Class information for:
Level 1: CYP2D6//DEBRISOQUINE//CYP2C19

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
1579 2503 40.0 78%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
395 16247 CYTOCHROME P450//CYP2D6//PREGNANE X RECEPTOR

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CYP2D6 Author keyword 229 41% 17% 429
2 DEBRISOQUINE Author keyword 140 72% 4% 110
3 CYP2C19 Author keyword 55 27% 7% 178
4 CYP2D6 POLYMORPHISM Author keyword 31 66% 1% 29
5 MEPHENYTOIN Author keyword 31 61% 1% 33
6 PHARMACOGENETICS Journal 27 16% 6% 153
7 DEXTROMETHORPHAN Author keyword 25 20% 5% 116
8 ULTRARAPID METABOLIZER Author keyword 23 86% 0% 12
9 POOR METABOLIZER Author keyword 22 57% 1% 26
10 CYP2D610 Author keyword 21 69% 1% 18

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CYP2D6 229 41% 17% 429 Search CYP2D6 Search CYP2D6
2 DEBRISOQUINE 140 72% 4% 110 Search DEBRISOQUINE Search DEBRISOQUINE
3 CYP2C19 55 27% 7% 178 Search CYP2C19 Search CYP2C19
4 CYP2D6 POLYMORPHISM 31 66% 1% 29 Search CYP2D6+POLYMORPHISM Search CYP2D6+POLYMORPHISM
5 MEPHENYTOIN 31 61% 1% 33 Search MEPHENYTOIN Search MEPHENYTOIN
6 DEXTROMETHORPHAN 25 20% 5% 116 Search DEXTROMETHORPHAN Search DEXTROMETHORPHAN
7 ULTRARAPID METABOLIZER 23 86% 0% 12 Search ULTRARAPID+METABOLIZER Search ULTRARAPID+METABOLIZER
8 POOR METABOLIZER 22 57% 1% 26 Search POOR+METABOLIZER Search POOR+METABOLIZER
9 CYP2D610 21 69% 1% 18 Search CYP2D610 Search CYP2D610
10 POOR METABOLIZERS 20 63% 1% 20 Search POOR+METABOLIZERS Search POOR+METABOLIZERS

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 DEBRISOQUINE 226 45% 15% 374
2 DEBRISOQUINE HYDROXYLATION 132 69% 5% 114
3 POOR METABOLIZERS 117 48% 7% 177
4 POOR METABOLIZER PHENOTYPE 92 71% 3% 75
5 S MEPHENYTOIN 80 39% 6% 162
6 MEPHENYTOIN 80 48% 5% 122
7 OXIDATION POLYMORPHISM 71 59% 3% 80
8 DEXTROMETHORPHAN O DEMETHYLATION 55 78% 1% 36
9 SPARTEINE METABOLISM 54 83% 1% 30
10 CYTOCHROME P450 2D6 53 35% 5% 124

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PHARMACOGENETICS 27 16% 6% 153

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry 2004 385 131 81%
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity 2005 387 49 69%
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants 2002 338 52 94%
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance Part I 2009 190 412 47%
Nomenclature for human CYP2D6 alleles 1996 270 30 87%
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs 2002 239 70 83%
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17 2010 72 36 53%
Pharmacogenomics of CYP2D6: Molecular Genetics, Interethnic Differences and Clinical Importance 2012 31 135 80%
Clinical significance of the cytochrome P4502C19 genetic polymorphism 2002 416 323 48%
The Promise of Psychiatric Pharmacogenomics 2015 3 76 22%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CICAB CLIN 12 58% 0.6% 14
2 SECT DEV PHARMACOL EXPT THER EUT 8 44% 0.6% 14
3 DEV PHARMACOL EXPT THER EUT 4 75% 0.1% 3
4 PHARMACOGENET CORE 4 75% 0.1% 3
5 NUCLEOTIDE POLYMORPHISM 3 60% 0.1% 3
6 SECT CLIN PHARMACOL EXPT THER EUT 3 60% 0.1% 3
7 EXPT PL NEUROPSYCHOPHARMACOL GRP 2 67% 0.1% 2
8 LANDESKLIN PSYCHIAT 1 2 67% 0.1% 2
9 MED PHARM CHUO KU 2 67% 0.1% 2
10 SUNNY BROOK WOMENS 2 67% 0.1% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000143814 PERHEXILINE//HYDROXYPERHEXILINE//PERHEXILINE MALEATE
2 0.0000137681 MARIE LOWE COMPARAT ONCOL//CYP2D//MARI LOWE COMPARAT ONCOL
3 0.0000132230 ENDOXIFEN//DESMETHYLTAMOXIFEN//N DESMETHYL TAMOXIFEN
4 0.0000126941 CYP3A//COCKTAIL//MECHANISM BASED INHIBITION
5 0.0000100613 CYP1A2//CAFFEINE METABOLISM//CYP1A2 ACTIVITY
6 0.0000094330 PHARMACOKINET BIOANAL//CYP2D19//PROPRANOLOL ENANTIOMER
7 0.0000092071 NORTRIPTYLINE//DESMETHYLCLOMIPRAMINE//DOXEPIN
8 0.0000091825 OPRM1//A118G//OPRM1 GENE
9 0.0000086286 MED HOSP PHARM YAHATANISHI KU//4 HYDROXYPROPRANOLOL//PROPRANOLOL METABOLISM
10 0.0000081708 PHARMACOGENOMICS//PERSONALIZED MEDICINE//PROGRAM PERSONALIZED MED TARGETED THER EUT